Send us Fan Mail

In this episode of the Biologics Brief, Mosaic Biosciences' Chief Strategy Officer Tracey Mullen sits down with Stacy Capehart, Director of Data Sciences at Mosaic, to talk about what happens after you find a promising antibody, and why finding one is not the same as finding a therapeutic candidate.

The conversation covers what developability actually means, the most common ways good antibodies fail (aggregation, viscosity and self-association, polyreactivity, and sequence liabilities like deamidation), which assays reveal each type of risk, and why timing is everything. They make the case for building developability into discovery early, while a panel of candidates still exists, rather than treating it as a late-stage veto after a team has already fallen in love with one molecule.

Topics covered:

• Defining developability: what separates "a molecule that works" from "a molecule that can become a drug"
• Aggregation risk: how it forms, what triggers it, and when it's actually a dealbreaker
• Viscosity and self-association, and why they matter most for high-concentration, subcutaneous dosing
• Polyreactivity: how a clean-binding antibody can still carry off-target risk
• Sequence liabilities like deamidation, oxidation, and unpaired cysteines, and why location and context determine impact
• How assays like AC-SINS, Tm, Tagg, HIC, and SEC each capture a different piece of the risk picture
• Why early developability data preserves optionality, while late data forces a rescue mission
• A rapid-fire round applying these principles to real trade-off scenarios

If your team is trying to build developability into your discovery workflow earlier rather than treating it as a late-stage surprise, reach out to Mosaic at mosaicbio.com, we'd be happy to walk through the right strategy for your program.

🎧 Listen now and subscribe wherever you get your podcasts.

mosaicbio.com

Send us Fan Mail

In this episode of the Biologics Brief, Mosaic Biosciences' Chief Strategy Officer Tracey Mullen leads a conversation on in vivo antibody discovery using humanized transgenic mice. She's joined by Dan Rohrer (Chief Technology Officer, AbTherx), along with Mosaic's Eric Firfine (Chief Scientific Officer), Maria Lo (Head of In Vivo Antibody Discovery), and Stacy Capehart (Director of Data Sciences).

The panel traces the evolution of transgenic mouse platforms from first-generation models through today's third-generation Atlas Mouse, discusses what "full human diversity" really means for downstream drug development, and covers how Mosaic decides which discovery platform, phage, yeast, single B cell, hybridoma, or transgenic mice, fits a given target. They also walk through a real CD22 discovery campaign, covering immunization strategy, hit identification, kinetic characterization, epitope binning, and developability profiling, and close with a look at where AI-generated antibody workflows fit alongside in vivo discovery.

Topics covered:

·       The evolution of transgenic mouse platforms and what makes the Atlas Mouse third-generation

·       What "full human diversity" means and why it matters for antibody discovery

·       Freedom to operate considerations often overlooked by bench scientists

·       How Mosaic selects the right discovery platform for a given target

·       A real-world CD22 discovery campaign: immunization, screening, and hit identification

·       Binding affinity, epitope binning, and developability results from the CD22 campaign

·       Strategies for managing large antibody hit panels without losing good candidates

·       Where AI-generated antibody workflows fit alongside in vivo discovery

If you're evaluating an in vivo discovery campaign or want to talk through the right platform strategy for a difficult target, reach out to the Mosaic team, we'd love to help.

🎧 Listen now and subscribe wherever you get your podcasts.

mosaicbio.com

Send us Fan Mail

Single B cell discovery has become one of the most powerful tools in antibody drug discovery, but with so many platforms on the market, how do you know which one is right for your campaign?

In this special Spotlight episode of The Biologics Brief, Mosaic Biosciences CSO Tracey Mullen sits down with Director of Antibody Discovery Christina Palmer to break down everything you need to know about single B cell discovery platforms, without the vendor spin.

What we cover:

• What single B cell discovery is and why adoption has surged in recent years
• The core trade-off between resolution and throughput, and why theoretical throughput numbers can be misleading
• How to compare the major platform categories: high-content optofluidic screening (Beacon), microfluidic droplet systems, sequencing-first workflows, and FACS-based platforms
• Why genotype-phenotype linkage matters more than most people realize
• How AI is changing the way antibody candidates are prioritized
• A practical 5-question framework for choosing the right single B cell workflow for your program

Whether you're a biotech team evaluating platforms for the first time or a seasoned drug discovery scientist looking to pressure-test your current approach, this episode gives you the tools to make a more informed decision.

About The Biologics Brief
The Biologics Brief is a podcast from Mosaic Biosciences, a biologics CRO specializing in antibody discovery and engineering. Each episode features conversations with scientists and industry experts on the topics that matter most in biologics drug development.

🎧 Listen now and subscribe wherever you get your podcasts.

mosaicbio.com

Single B cell discovery has become one of the most powerful tools in antibody drug discovery, but with so many platforms on the market, how do you know which one is right for your campaign?

In this special Spotlight episode of The Biologics Brief, Mosaic Biosciences CSO Tracey Mullen sits down with Director of Antibody Discovery Christina Palmer to break down everything you need to know about single B cell discovery platforms, without the vendor spin.

What we cover:

• What single B cell discovery is and why adoption has surged in recent years
• The core trade-off between resolution and throughput, and why theoretical throughput numbers can be misleading
• How to compare the major platform categories: high-content optofluidic screening (Beacon), microfluidic droplet systems, sequencing-first workflows, and FACS-based platforms
• Why genotype-phenotype linkage matters more than most people realize
• How AI is changing the way antibody candidates are prioritized
• A practical 5-question framework for choosing the right single B cell workflow for your program

Whether you're a biotech team evaluating platforms for the first time or a seasoned drug discovery scientist looking to pressure-test your current approach, this episode gives you the tools to make a more informed decision.

About The Biologics Brief
The Biologics Brief is a podcast from Mosaic Biosciences, a biologics CRO specializing in antibody discovery and engineering. Each episode features conversations with scientists and industry experts on the topics that matter most in biologics drug development.

🎧 Listen now and subscribe wherever you get your podcasts.

mosaicbio.com

Single B cell discovery has become one of the most powerful tools in antibody drug discovery, but with so many platforms on the market, how do you know which one is right for your campaign?

In this special Spotlight episode of The Biologics Brief, Mosaic Biosciences CSO Tracey Mullen sits down with Director of Antibody Discovery Christina Palmer to break down everything you need to know about single B cell discovery platforms, without the vendor spin.

What we cover:

• What single B cell discovery is and why adoption has surged in recent years
• The core trade-off between resolution and throughput, and why theoretical throughput numbers can be misleading
• How to compare the major platform categories: high-content optofluidic screening (Beacon), microfluidic droplet systems, sequencing-first workflows, and FACS-based platforms
• Why genotype-phenotype linkage matters more than most people realize
• How AI is changing the way antibody candidates are prioritized
• A practical 5-question framework for choosing the right single B cell workflow for your program

Whether you're a biotech team evaluating platforms for the first time or a seasoned drug discovery scientist looking to pressure-test your current approach, this episode gives you the tools to make a more informed decision.

About The Biologics Brief
The Biologics Brief is a podcast from Mosaic Biosciences, a biologics CRO specializing in antibody discovery and engineering. Each episode features conversations with scientists and industry experts on the topics that matter most in biologics drug development.

🎧 Listen now and subscribe wherever you get your podcasts.

mosaicbio.com

The Biologics Brief: Spotlight | Single B Cell Discovery: Platforms, Trade-offs, and How to Actually Choose

Single B cell discovery has become one of the most powerful tools in antibody drug discovery, but with so many platforms on the market, how do you know which one is right for your campaign?

In this special Spotlight episode of The Biologics Brief, Mosaic Biosciences CSO Tracey Mullen sits down with Director of Antibody Discovery Christina Palmer to break down everything you need to know about single B cell discovery platforms, without the vendor spin.

What we cover:

• What single B cell discovery is and why adoption has surged in recent years
• The core trade-off between resolution and throughput, and why theoretical throughput numbers can be misleading
• How to compare the major platform categories: high-content optofluidic screening (Beacon), microfluidic droplet systems, sequencing-first workflows, and FACS-based platforms
• Why genotype-phenotype linkage matters more than most people realize
• How AI is changing the way antibody candidates are prioritized
• A practical 5-question framework for choosing the right single B cell workflow for your program

Whether you're a biotech team evaluating platforms for the first time or a seasoned drug discovery scientist looking to pressure-test your current approach, this episode gives you the tools to make a more informed decision.

About The Biologics Brief
The Biologics Brief is a podcast from Mosaic Biosciences, a biologics CRO specializing in antibody discovery and engineering. Each episode features conversations with scientists and industry experts on the topics that matter most in biologics drug development.

🎧 Listen now and subscribe wherever you get your podcasts.

mosaicbio.com

The Biologics Brief: Spotlight | Single B Cell Discovery: Platforms, Trade-offs, and How to Actually Choose

Single B cell discovery has become one of the most powerful tools in antibody drug discovery, but with so many platforms on the market, how do you know which one is right for your campaign?

In this special Spotlight episode of The Biologics Brief, Mosaic Biosciences CSO Tracey Mullen sits down with Director of Antibody Discovery Christina Palmer to break down everything you need to know about single B cell discovery platforms, without the vendor spin.

What we cover:

• What single B cell discovery is and why adoption has surged in recent years
• The core trade-off between resolution and throughput, and why theoretical throughput numbers can be misleading
• How to compare the major platform categories: high-content optofluidic screening (Beacon), microfluidic droplet systems, sequencing-first workflows, and FACS-based platforms
• Why genotype-phenotype linkage matters more than most people realize
• How AI is changing the way antibody candidates are prioritized
• A practical 5-question framework for choosing the right single B cell workflow for your program

Whether you're a biotech team evaluating platforms for the first time or a seasoned drug discovery scientist looking to pressure-test your current approach, this episode gives you the tools to make a more informed decision.

About The Biologics Brief
The Biologics Brief is a podcast from Mosaic Biosciences, a biologics CRO specializing in antibody discovery and engineering. Each episode features conversations with scientists and industry experts on the topics that matter most in biologics drug development.

🎧 Listen now and subscribe wherever you get your podcasts.

mosaicbio.com

Send us Fan Mail

Your antibody program doesn’t fail because you picked the “wrong platform” as often as it fails because you picked the wrong partner. We get specific about how to choose a preclinical CRO for antibody discovery by starting with the one thing that should drive every decision: the target clinical profile. If the CRO can’t translate your clinical goals into a practical, testable preclinical plan, you’re not buying confidence, you’re buying activity.

We talk about why outsourcing is so common across biotech and pharma, from capital efficiency to speed, and why a disease-agnostic contract research organization can be an advantage when you need battle-tested execution. Then we dig into what “fully integrated” really means in biologics development: not just finding antibody sequences, but carrying knowledge into functional assays, pharmacology, stability, developability, and the steps that support IND-enabling work.

We also cover the biggest traps buyers fall into when comparing CRO quotes. A low price can hide missing deliverables, thin characterization, or a handoff that leaves you hunting for the next vendor. You’ll hear the exact questions we think you should ask before you sign: what you get at the end of the first round, what minimum product is delivered if the campaign underperforms, who runs your program, and whether the CRO can clearly explain the pros and cons of different antibody discovery approaches for your target. If you find this useful, subscribe, share it with a teammate, and leave a review with the one CRO question you wish you had asked sooner.

mosaicbio.com

🎧 Listen now and subscribe wherever you get your podcasts.

mosaicbio.com